Last update 09 Dec 2025

SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms-
Target
SARS-CoV-2 antigen
Action
inhibitors
Mechanism
SARS-CoV-2 antigen inhibitors
Therapeutic Areas
NeoplasmsInfectious DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
COVID-19Hematologic NeoplasmsMalignant Solid Neoplasm
Inactive Indication-
Originator Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)
NCT04742595
/ CompletedEarly Phase 1IIT
Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients With Cancer
100 Clinical Results associated with SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)
Login to view more data
100 Deals associated with SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes(M.D. Anderson Cancer Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
18 Dec 2020
Hematologic NeoplasmsPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
18 Dec 2020
Malignant Solid NeoplasmPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
18 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free